LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Lista de Ações・uniQure NV

uniQure NV

Fechado

29.1 5.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

26.99

Máximo

29.77

Indicadores-chave
By Trading Economics
Rendimento	-16M -54M
Vendas	-2M 3.6M
EPS	-0.727
Margem de lucro	-1,502.948
Funcionários	221
EBITDA	13M -36M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+40.38% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	440M 1.7B
Abertura anterior	23.63
Fecho anterior	29.1

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

10.05 / 14.75 Suporte e Resistência

uniQure NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de mar. de 2026, 13:13 UTC

Grandes Movimentos do Mercado

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 de jan. de 2026, 15:14 UTC

Grandes Movimentos do Mercado

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 de nov. de 2025, 13:34 UTC

Grandes Movimentos do Mercado

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 de set. de 2025, 18:51 UTC

Ganhos

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Comparação entre Pares

Variação de preço

uniQure NV Previsão

Preço-alvo

By TipRanks

40.38% parte superior

Previsão para 12 meses

Média 38.8 USD 40.38%

Máximo 95 USD

Mínimo 9 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para uniQure NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para uniQure NV - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

10.05 / 14.75Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.